Multiple Tumor Types

« Previous 12345 Next »
Viewing Page 1 of 6 | Showing Results 1 - 10 of 56

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and...

Walter Urba, M.D., Ph.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

A Phase 1/2, Open-Label, Multicenter, Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies.

In this four part study, NKTR-214 will be administered in combination with nivolumab in Parts 1 & 2, and with nivolumab and ipilimumab in Parts 3 &...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

ZWI-ZW25-101 (anti-Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

Molecular Analysis for Therapy Choice (MATCH)

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 2, Open-Label, Multi-Cohort Combination Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors,...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

Pilot program to assess the potential role of pharmacogenomics to improve drug safety in patients with advanced cancer.

The purpose of this study is to determine if a drug safety program based on pharmacogenetics (the study of how a person’s genes respond to drugs),...

Michael Demeure, M.D.
  • xSJH Southern California

A phase 1 study of SGN-CD47M in patients with advanced solid tumors.

This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability,...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

CriteriaPartial Inclusion Criteria:Patient with advanced or metastatic solid tumor and has disease progression or treatment intolerance after...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research
« Previous 12345 Next »
Viewing Page 1 of 6 | Showing Results 1 - 10 of 56